Evidence map›Paper›PMID 23247392›Full record

ArticleJournal of molecular and cellular cardiology2013

Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties.

Euy-Myoung Jeong, Michelle M Monasky, Lianzhi Gu, Domenico M Taglieri, Bindiya G Patel, Hong Liu, Qiongying Wang, Ian Greener, Samuel C Dudley, R John Solaro

Abstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Targeting PKGIα CysScience advances · 2026
    Article
  3. Article
  4. Article
  5. Early pathological mechanisms in a mouse model of heart failure with preserved ejection fraction.American journal of physiology. Heart and circulatory physiology · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Euy-Myoung JeongDepartment of Medicine, Section of Cardiology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Michelle M Monasky
Lianzhi Gu
Domenico M Taglieri
Bindiya G Patel
Hong Liu
Qiongying Wang
Ian Greener
Samuel C Dudley
R John Solaro
University of Illinois Chicago · US

Funding

Sarcomeric Modifications and Progressive Cardiac MaladaptationP01HL062426 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN · 2000 to 2020
$42.4M
Vascular specific ACE expression and atherosclerosisP01HL058000 · NHLBI · VANDERBILT UNIVERSITY · PI DIKALOV, SERGEY · 1998 to 2013
$20.7M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR029879 · NCRR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MAZZONE, THEODORE · 2009 to 2011
$11.0M
TRAINING IN CELLULAR SIGNALLING IN THE CARDIOVASCULAR SYT32HL007692 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN · 1990 to 2014
$8.5M
Troponin Mudulation in Heart FailureR01HL064035 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN, WOLSKA, BEATA M. · 2000 to 2013
$4.7M
MODULATION OF CALCIUM CONTROL OF CARDIAC MYOFIBRILSR01HL022231 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GUPTA, MADHU, SOLARO, R JOHN · 1985 to 2014
$2.9M
Angiotensin converting enzyme, angiotensin II, and arrhythmiaR01HL085558 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDLEY, SAMUEL C · 2007 to 2010
$1.5M
Stem Cell Therapy and ArrhythmiaR01HL073753 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDLEY, SAMUEL C · 2005 to 2008
$1.4M
NCRR NIH HHS UL1 RR029879NCRR NIH HHS UL1RR029879NHLBI NIH HHS P01 HL058000NHLBI NIH HHS P01 HL062426NHLBI NIH HHS R01 HL022231NHLBI NIH HHS R01 HL064035NHLBI NIH HHS R01 HL073753NHLBI NIH HHS R01 HL085558NHLBI NIH HHS T32 HL007692NHLBI NIH HHS T32 HL07692-16-20
6 · The paper itself

Abstract

Despite the increasing prevalence of heart failure with preserved left ventricular function, there are no specific treatments, partially because the mechanism of impaired relaxation is incompletely understood. Evidence indicates that cardiac relaxation may depend on nitric oxide (NO), generated by NO synthase (NOS) requiring the co-factor tetrahydrobiopterin (BH(4)). Recently, we reported that hypertension-induced diastolic dysfunction was accompanied by cardiac BH(4) depletion, NOS uncoupling, a depression in myofilament cross-bridge kinetics, and S-glutathionylation of myosin binding protein C (MyBP-C). We hypothesized that the mechanism by which BH(4) ameliorates diastolic dysfunction is by preventing glutathionylation of MyBP-C and thus reversing changes of myofilament properties that occur during diastolic dysfunction. We used the deoxycorticosterone acetate (DOCA)-salt mouse model, which demonstrates mild hypertension, myocardial oxidative stress, and diastolic dysfunction. Mice were divided into two groups that received control diet and two groups that received BH(4) supplement for 7days after developing diastolic dysfunction at post-operative day 11. Mice were assessed by echocardiography. Left ventricular papillary detergent-extracted fiber bundles were isolated for simultaneous determination of force and ATPase activity. Sarcomeric protein glutathionylation was assessed by immunoblotting. DOCA-salt mice exhibited diastolic dysfunction that was reversed after BH(4) treatment. Diastolic sarcomere length (DOCA-salt 1.70±0.01 vs. DOCA-salt+BH(4) 1.77±0.01μm, P<0.001) and relengthening (relaxation constant, τ, DOCA-salt 0.28±0.02 vs. DOCA-salt+BH(4) 0.08±0.01, P<0.001) were also restored to control by BH(4) treatment. pCa(50) for tension increased in DOCA-salt compared to sham but reverted to sham levels after BH(4) treatment. Maximum ATPase rate and tension cost (ΔATPase/ΔTension) decreased in DOCA-salt compared to sham, but increased after BH(4) treatment. Cardiac MyBP-C glutathionylation increased in DOCA-salt compared to sham, but decreased with BH(4) treatment. MyBP-C glutathionylation correlated with the presence of diastolic dysfunction. Our results suggest that by depressing S-glutathionylation of MyBP-C, BH(4) ameliorates diastolic dysfunction by reversing a decrease in cross-bridge turnover kinetics. These data provide evidence for modulation of cardiac relaxation by post-translational modification of myofilament proteins.

Indexed as

Adenosine TriphosphatasesAdministration, OralAnimalsBiopterinsCardiovascular AgentsCarrier ProteinsCells, CulturedDesoxycorticosteroneDiastoleDietary SupplementsGlutathioneHeart Failure, DiastolicMiceMyofibrilsMyosin Binding Protein COxidative StressAdenosine TriphosphatasesBiopterinsCardiovascular AgentsCarrier ProteinsDesoxycorticosteroneGlutathioneMyosin Binding Protein Csapropterin

Identifiers

PMID23247392
PMCPMC3666585
OpenAlexW2088374043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.